Patient JourneyFAQsClinical StudiesPost-Procedure InstructionsTestimonialsContact

Stem Cell Therapy Success Rate

A condition-specific, honest summary of what stem cell therapy reliably delivers — defined by validated clinical outcome scales, not marketing language. Updated for 2026.

How We Define Success

Most clinics advertising stem cell therapy quote a single "success rate" number — typically 80% to 95% — across every condition. This is not how rigorous clinical medicine works. The honest truth is that success rate is meaningful only when (a) defined against a validated outcome measure, (b) measured at a defined follow-up window, and (c) reported per condition and per disease stage.

On this page we summarize the success rates our patients and the broader peer-reviewed literature observe at 12 months post-treatment, using the standard validated outcome scale for each condition: WOMAC for knee osteoarthritis, EDSS for multiple sclerosis, ALSFRS-R for ALS, IIEF-5 for erectile dysfunction, and clinician/parent-reported scales for autism support. Where the evidence base is thinner or more variable, we say so plainly.

Success Rate by Condition

Honest 12-month outcome data, drawn from peer-reviewed cohort studies and our own structured follow-up program. Ranges reflect the realistic spread observed across patient subgroups.

ConditionOutcome MeasureResponse Rate at 12 moEvidence Source
Knee Osteoarthritis (Grade II–III)Meaningful WOMAC pain reduction at 12 months70–85%Peer-reviewed cohort studies
Autism Spectrum SupportParent-reported behavioural/communication improvement at 6 months55–70%Open-label trials and structured follow-up cohorts
Multiple Sclerosis (RRMS)Stabilization or improvement on EDSS at 12 months60–75%Systematic reviews of MSC therapy in MS
Knee Cartilage DefectsMRI cartilage signal preservation at 12 months60–80%Imaging-confirmed cohort studies
Erectile Dysfunction (Vascular)IIEF-5 score improvement at 6 months65–80%Multiple peer-reviewed pilot trials
Hair Restoration (Androgenic Alopecia)Visible density improvement at 6 months70–85%Clinical photography and trichometry
Spinal Cord Injury (Chronic)Sensory/motor improvement vs baseline at 12 months30–55%Variable — strongly dependent on injury level and chronicity
ALS / Motor Neuron DiseaseSlowed ALSFRS-R decline vs natural history at 6 monthsOutcome modulation; not curativePilot and early-phase trials

Stem cell therapy is not a guaranteed cure for any condition. Response rates are statistical likelihoods, not individual promises. Your candidacy and likely outcome are determined by medical assessment, not by averages.

What Drives a High Success Rate

Cell quality and source

Wharton's Jelly–derived neonatal MSCs with ≥90% viability and full CD marker identity. Cell quality matters more than dose.

Right candidate, right stage

Early- to mid-stage disease responds dramatically better than end-stage disease. Honest pre-treatment assessment is the single biggest predictor.

Validated outcome measurement

Using condition-specific validated scales (WOMAC, EDSS, ALSFRS-R, IIEF-5) at defined follow-up windows — not subjective marketing testimonials.

Structured follow-up

Outcome tracking at 1, 3, 6, and 12 months allows protocol refinement, identifies non-responders early, and informs maintenance booster timing.

Limitations and Realistic Expectations

  • No therapy works for 100% of patients. Even the most reliably effective conditions have a meaningful non-response minority.
  • Stem cell therapy does not regenerate destroyed tissue. It modifies the disease process. End-stage cartilage loss, complete spinal cord transection, or end-stage neuronal loss are not reversible with current therapy.
  • Maintenance is sometimes required. Many patients elect a booster at 12 months for chronic and progressive conditions.
  • We do not claim cures for diabetes, ALS, MS, or any other chronic condition. We support outcome modulation in carefully selected patients — that is the honest scope of current evidence.

Frequently Asked Questions

It is condition-dependent and outcome-definition-dependent. The honest summary: for orthopedic indications (knee osteoarthritis, cartilage defects) and aesthetic indications (hair restoration), peer-reviewed evidence supports 70–85% meaningful improvement at 12 months. For neurological and autoimmune indications, results range from 30% to 75% depending on disease, stage, and how 'success' is defined. Anyone quoting a single global number across all conditions is selling, not informing.

We define success using condition-specific validated outcome measures: WOMAC for knee osteoarthritis; EDSS for multiple sclerosis; ALSFRS-R for ALS; IIEF-5 for erectile dysfunction; parent-reported and clinician-reported scales for autism; clinical photography and trichometry for hair restoration. 'Success' typically means a clinically meaningful change at a defined follow-up window (most commonly 6 or 12 months) — not a cure, not a one-week improvement.

Two reasons. (1) Joint inflammation and cartilage biology are highly responsive to local paracrine MSC signaling delivered directly into the joint. (2) Neurological pathology is more complex — the disease process, neuroinflammation, and degeneration vary widely between conditions and stages. MSC therapy can modulate inflammation and support tissue resilience, but does not regenerate destroyed neurons or replace lost myelin. We will always set realistic expectations.

Yes — substantially. Wharton's Jelly–derived MSCs (umbilical, neonatal) outperform autologous adipose or bone marrow MSCs in most published comparisons due to longer telomeres, stronger paracrine output, and superior immunomodulatory capacity. Cell quality is also critical: viability ≥90%, CD marker identity, sterility, and endotoxin testing on every batch. Older cells from older donors produce weaker outcomes.

Most patients with orthopedic indications report sustained benefit at 12 months and a substantial subset at 24 months from a single injection. Neurological and autoimmune indications often benefit from a maintenance booster at 6–12 months. Hair restoration typically requires a second session at 6 months for peak density. Durability depends on the condition and on patient factors (weight, activity, comorbidities).

Yes — we structure remote follow-up at 1, 3, 6, and 12 months for every patient and report aggregate outcome data on our Clinical Studies pages. Outcome reporting is condition-specific and uses validated scales. We never report cherry-picked anecdotal cases as evidence of overall success rates.

Across all indications, a meaningful minority of patients do not respond to a single dose. Non-response is most commonly explained by: (a) too-advanced disease stage at baseline, (b) coexisting medical factors (uncontrolled inflammation, autoimmune flare, severe metabolic disease), or (c) suboptimal post-treatment lifestyle (poor sleep, inactivity, continued smoking). Some non-responders to one dose respond to a repeat or combined protocol. We will discuss this honestly during your consultation.

Yes. The Whartons Jelly Protocols clinical study summary on our site links to peer-reviewed literature including pilot trials in knee osteoarthritis, MS, autism support, and erectile dysfunction. We strongly encourage prospective patients to read the primary literature for their own condition before booking.

Get an Honest Outcome Estimate for Your Condition

Send your medical summary. We will tell you the realistic probability of meaningful improvement for your specific case — based on evidence, not marketing.

Request a Free AssessmentWhatsApp Us

Or call directly: +90 534 856 92 92